New hope for taming a rare and relapsing autoimmune disease

This study tested whether a drug called rituximab is better than standard therapy at getting a rare inflammatory blood vessel disease (EGPA) into remission and keeping it there. It involved 107 adults with newly diagnosed or flaring EGPA, who were randomly assigned to receive either rituximab or conventional treatment. The goal was to see which approach was more effective at controlling the disease while allowing patients to reduce their steroid use.